Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inactive Ingredients Exemption From Labeling Rule Sought By Zee Medical

This article was originally published in The Tan Sheet

Executive Summary

Zee Medical is seeking FDA exemption from OTC labeling rule requirements that each inactive ingredient be listed on a product. In a Sept. 15 application, the company requests it be "allowed to use the phrase 'may contain' to list inactive ingredients that may or may not be present" in its PainAid Pain Relief tablets.

You may also be interested in...



Bactec Kit Outer Labeling Only Required To Comply With “Drug Facts” Format

The individual OTC components in Becton Dickinson's Bactec Blood Culture Procedural Tray will not be required to carry "Drug Facts" labeling as long as the kit's outer package uses the OTC labeling format to describe the components, FDA says in a June 5 letter to the firm

Bactec Kit Outer Labeling Only Required To Comply With “Drug Facts” Format

The individual OTC components in Becton Dickinson's Bactec Blood Culture Procedural Tray will not be required to carry "Drug Facts" labeling as long as the kit's outer package uses the OTC labeling format to describe the components, FDA says in a June 5 letter to the firm

Bactec Kit Outer Labeling Only Required To Comply With “Drug Facts” Format

The individual OTC components in Becton Dickinson's Bactec Blood Culture Procedural Tray will not be required to carry "Drug Facts" labeling as long as the kit's outer package uses the OTC labeling format to describe the components, FDA says in a June 5 letter to the firm

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel